Back

Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Antidiabetic medications and cardiovascular disease Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Ryoma Kani

Kameda Medical Center, Kamogawa (Japan)

6 More presentations in this session

Presentation thumbnail
Effects of SGLT2i on reducing risks of cardiovascular events and dementia in atrial fibrillation patients with diabetes mellitus: a nationwide cohort study
Assistant Professor Y. Chen (Taichung, TW)
Abstract Slides Video
Presentation thumbnail
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in patients with atrial fibrillation and type 2 diabetes mellitus
Professor Y. Oh (Seoul, KR)
Abstract Slides
Presentation thumbnail
GLP1-RA versus metformin as first-line therapy for achieving glycemic control and risk-factor management - a one-year nationwide cohort study
Ms K. Soerensen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
The renal outcome post contrast exposure in patient with diabetes and SGLT2 inhibitor
Doctor C. Chen (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset hip fracture risks in patients with type-2 diabetes: A propensity sc
Professor G. Tse (Hong Kong, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Antidiabetic medications and cardiovascular disease

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting
thumbnail
Congress Presentation
Hypertension and glucose
thumbnail
Congress Presentation
Cardiovascular risk reduction: should we target pre-diabetes?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources